lovastatin has been researched along with Flushing in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brinton, EA; Jiang, P; Kashyap, ML; Padley, RJ; Thakkar, RB; Vo, AN | 1 |
| Cefali, E; Menon, R; Tolbert, D | 1 |
1 trial(s) available for lovastatin and Flushing
| Article | Year |
|---|---|
The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Flushing; Humans; Lovastatin; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Niacin; Niacinamide; Nicotinic Acids; Pyridones; Tablets; Time Factors; Vitamin B Complex | 2007 |
1 other study(ies) available for lovastatin and Flushing
| Article | Year |
|---|---|
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Topics: Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Medication Adherence; Middle Aged; Niacin; Simvastatin | 2011 |